| Trial ID: | L5350 |
| Source ID: | NCT00747175
|
| Associated Drug: |
Azd1656
|
| Title: |
A Study to Evaluate Safety, Tolerability and P-Glucose After Multiple Ascending Oral Doses of AZD1656 in Type 2 Diabetes
|
| Acronym: |
MAD
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: AZD1656|DRUG: AZD1656
|
| Outcome Measures: |
Primary: Safety variables (AE, BP, pulse, plasma glucose, laboratory variables and ECG), Blood samples taken repeatedly during 24 hours on study day sessions | Secondary: Pharmacokinetic variables, Blood samples taken repeatedly during 24 hours on study day sessions|Pharmacodynamic variables, Blood samples taken repeatedly during 24 hours on study day sessions
|
| Sponsor/Collaborators: |
Sponsor: AstraZeneca
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
52
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT
|
| Start Date: |
2008-08
|
| Completion Date: |
2009-04
|
| Results First Posted: |
|
| Last Update Posted: |
2010-12-03
|
| Locations: |
Research Site, Chula Vista, California, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00747175
|
